Re: PAH

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Prev Message Back To Forum Threaded View Next Message

golfyeti

Rank: Vice President [?]

Points: 23990 [?]

Votes: 216 Score: 3.2 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: PAH

in response to

Re: PAH

KOO-KOO2

posted on Jul 12, 2022 12:03PM

It is described as an "extension" of the previous pilot trial (conducted by Laval Universite) https://clinicaltrials.gov/ct2/show/NCT03655704 Which was completed.

I found a P2 with investigator U of Laval P2 (Approach2). "Not yet recruiting" is the status and may have been abandoned (?): https://clinicaltrials.gov/ct2/show/NCT04915300

The extension referred to in this new trial appears to be sponsored by the NIH*.

https://phassociation.org/apabetalone-for-pulmonary-arterial-hypertension-a-pilot-study-approach-p/

Population: PAH

Start Date: June 14, 2022

End Date: October 14, 2022

Phase: Observational

*Institution: NIH

Study Summary

The main objective of this proposal is to extend the investigator’s preclinical findings on the role of epigenetics and DNA damage and Bromodomain-Containing Protein 4 (BRD4) inhibition as a therapy for a devastating disease, pulmonary arterial hypertension (PAH).

9 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply